Rosacea Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Rosacea Market is segmented by Drug Class (Antibiotics, Alpha Agonists, Retinoid, Corticosteroids, Immunosuppressants, and Other Drug Classes), Mode of Administration (Topics and Oral), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers the value (in USD million) for the above segments.

Market Snapshot

Rosacea Market Size
Study Period: 2019-2027
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 6.21 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The rosacea market is expected to register a CAGR of 6.21% over the forecast period.

COVID-19 is expected to have an impact on the growth of the market during the pandemic period. This is mainly due to the worsening of the rosacea condition due to the COVID-19 protection kits. According to the article titled " Galderma online survey reveals essential COVID-19 mask wearing can be worsening rosacea skin disease" published in February 2021 a recent survey conducted by Galderma suggested that the pandemic may impact rosacea patients, by worsenings of signs and symptoms related to mask-wearing and there were reduced healthcare professionals consultations. Thus, the demand for rosacea treatment due to the COVID-19 outbreak is expected to contribute to the growth of the market during the pandemic period.

The growth of the market is attributed to the factors such as the increasing prevalence of rosacea among the global population. For instance, the article titled " Epidemiology of rosacea in a population-based of 161,269 German employees" published in December 2021 mentioned that 2.1% of the survey participants had rosacea. the prevalence of rosacea increased significantly with age. The report also mentioned that Rosacea is a common skin condition that is most prevalent above the age of 65 years. According to World Health Organization (WHO) data published in October 2021, by 2030, 1 in 6 people in the world will be aged 60 years or over. The share of the population aged 60 years and over will increase from 1 billion in 2020 to 1.4 billion. By 2050, the world’s population of people aged 60 years and older will double (2.1 billion). The number of persons aged 80 years or older is expected to triple between 2020 and 2050 to reach 426 million. Rosacea is a common skin disease, which causes redness and visible blood vessels on the face. It commonly affects middle-aged women who have fair skin. Although there is no cure for rosacea, treatments can control and reduce the signs and symptoms associated with the disease. It has been observed in several studies that this is more common in fair-skinned individuals.

With rising prevalence, the awareness among physicians and societies has also increased, which further drives the demand for this market. However, the presence of generic drugs to curb the related symptoms hinders the growth of the rosacea market.

Scope of the Report

As per the scope of the market, rosacea is a condition diagnosed by symptoms, such as facial flushing, coarseness of skin, and an inflammatory papulopustular eruption resembling acne. The Rosacea Market is segmented by Drug Class (Antibiotics, Alpha Agonists, Retinoid, Corticosteroids, Immunosuppressants, and Other Drug Classes), Mode of Administration (Topics and Oral), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.

By Drug Class
Antibiotics
Alpha Agonists
Retinoid
Corticosteroids
Immunosuppressants
Other Drug Classes
By Mode of Administration
Topical
Oral
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Antibiotics is Estimated to Witness Healthy Growth Over the Forecast Period

Antibiotics have been prescribed as a treatment for the symptoms of rosacea for a long period. It can reduce the number of acne pimples and bacterial inflammation or redness around the acne pimples. Antibiotics are available in two forms, including oral antibiotics and topical antibiotics.

Oral antibiotics, such as tetracycline, doxycycline, and minocycline, have been proven to control rosacea's bacterial component and also have inflammatory benefits. According to the article titled " Doxycycline" updated in June 2022 doxycycline is used only to treat pimples and bumps caused by rosacea. It is most commonly preferred by physicians and doctors for early relief from the disease but is usually for a long period, which drives the sales of this segment over other sub-segments. So, the high usage of antibiotics for the treatment of rosacea is the main factor for the growth of the market. According to the article titled " Rosacea Medication" published in June 2021 topical and oral antibiotics are also very effective and for oral rosacea, they are usually considered first-line therapy. Furthermore, in the article titled " What treatment Options are available for Rosacea?" published in August 2021 Metronidazole is an antibiotic cream or gel used to treat rosacea. The study also mentioned that patients who regularly used metronidazole saw their rosacrea-related pustules and papules by between 40 and 65%. Such reduction of rosacea related skin conditions are expected to contribute to the growth of the studied segment. Thus the above mentioned factors are expected to drive the growth of the studied segment over the forecast period.

123

North America is Expected to Maintain the Largest Share in the Rosacea Market Over the Forecast Period

North America has multiple factors, which support the growth of this market, better than other geographic regions. Some factors include high healthcare expenditure by the government each year on pharmaceuticals and medical devices and awareness in society. According to the article titled " National Organization Brings awareness to rosacea treatments" published in March 2021, The National Rosacea society designed April as Rosacea Awareness Month to educate the public on this potentially serious disorder. Moreover, as per the article titled " Rosacea: What to know about causes, triggers and treatment" published in September 2021, about 16 million Americans suffer from rosacea and maybe millions more are in temporary remission. Moreover, the companies also prefer to release their products first in the United States, due to favorable regulatory requirements, which drive the demand for this market. For instance, in April 2022 the Food and Drug Administration approved a proprietary cream formulation of benzoyl peroxide 5% (EPSOLAY) for the treatment of inflammatory lesions of rosacea.

Additionally, the market players' strategies are expected to drive the growth of the market in this region. For instance, in July 2021 Sol-Gel technologies and Galderma announced the signing of two exclusive five-year license agreements for the commercialization of Epsolay and Twyneo in the United States.

Thus, the above-mentioned factors are expected to drive the growth of the market in this region over the forecast period.

12

Competitive Landscape

The Rosacea market is consolidated in nature due to the presence of a few companies operating globally as well as regionally. The rosacea market has observed growing competition among leading players, majorly across the developed markets. Some of the major market players include Bausch Health Companies Inc., Amorepacific Corporation, Nestlé (Galderma), Leo Pharma Inc., Hovione FarmaCiencia SA, and Aclaris Therapeutics, among others.

Major Players

  1. Aclaris Therapeutics

  2. Leo Pharma Inc.

  3. Hovione FarmaCiencia SA

  4. Bausch Health Companies

  5. Nestlé

Rosacea- MC.jpg

Recent Development

  • In April 2022 the Food and Drug Administration approved a proprietary cream formulation of benzoyl peroxide 5% (EPSOLAY) for the treatment of inflammatory lesions of rosacea.
  • In July 2021 Sol-Gel technologies and Galderma announced the signing of two exclusive five-year license agreements for the commercialization of Epsolay and Twyneo in the United States.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Incidence and Prevalence of Rosacea

      2. 4.2.2 Increasing Inclination toward Combination Products

    3. 4.3 Market Restraints

      1. 4.3.1 Increased Use of Generic Drugs

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value – USD million)

    1. 5.1 By Drug Class

      1. 5.1.1 Antibiotics

      2. 5.1.2 Alpha Agonists

      3. 5.1.3 Retinoid

      4. 5.1.4 Corticosteroids

      5. 5.1.5 Immunosuppressants

      6. 5.1.6 Other Drug Classes

    2. 5.2 By Mode of Administration

      1. 5.2.1 Topical

      2. 5.2.2 Oral

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Aclaris Therapeutics

      2. 6.1.2 Amorepacific Corporation

      3. 6.1.3 Bausch Health Companies Inc.

      4. 6.1.4 Hovione FarmaCiencia SA

      5. 6.1.5 Leo Pharma Inc.

      6. 6.1.6 Nestlé

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments
You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global Rosacea Market market is studied from 2019 - 2027.

The Global Rosacea Market is growing at a CAGR of 6.21% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Aclaris Therapeutics, Leo Pharma Inc., Hovione FarmaCiencia SA, Bausch Health Companies, Nestlé are the major companies operating in Global Rosacea Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!